002800 — Sinsin Pharmaceutical Co Income Statement
0.000.00%
- KR₩96bn
- KR₩140bn
- KR₩103bn
- 53
- 41
- 19
- 28
Annual income statement for Sinsin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 67,855 | 67,129 | 74,008 | 91,926 | 102,586 |
Cost of Revenue | |||||
Gross Profit | 23,579 | 18,514 | 21,774 | 30,301 | 33,408 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 65,823 | 71,298 | 75,368 | 86,500 | 96,582 |
Operating Profit | 2,032 | -4,170 | -1,361 | 5,426 | 6,004 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,131 | -269 | -1,747 | 4,047 | 3,995 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2,024 | 201 | -1,449 | 4,355 | 4,646 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2,138 | 363 | -1,476 | 4,415 | 4,680 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2,138 | 363 | -1,476 | 4,415 | 4,680 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 160 | -172 | -96.5 | 289 | 308 |
Dividends per Share |